CRB2 Facilitates Epithelial Ovarian Cancer Progression by Inducing Polarity Changes via Activation of the Wnt/ PCP Signalling Pathway
Journal of Cellular and Molecular Medicine · 2026-04 · 30 (7)
DOI: 10.1111/jcmm.71124 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 29.03.2026. Verfasst von Chunlin Tao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital South Campu, Shanghai, China. Hauptthemen laut MEDLINE: Cell Polarity, Carcinoma, Ovarian Epithelial, Wnt Signaling Pathway, Ovarian Neoplasms. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Social Science and Technology Development Fund of Fengxian District Science and Technology Commission.
Abstract (Originalsprache)
Ovarian cancer exhibits high molecular heterogeneity and metastatic potential, contributing to its status as a leading cause of gynecologic cancer mortality. Cell polarity is essential in tumorigenesis, yet the role of Crumbs family proteins (CRBs), key regulators of apical–basal polarity, in epithelial ovarian cancer (EOC) remains unclear. In this study, we analysed CRB expression profiles using TCGA and GEO datasets, and validated our findings through immunohistochemical staining of ovarian tumour tissue microarrays. Among CRBs, CRB2 was significantly overexpressed in EOC tissues and correlated with poor patient prognosis. Functional assays revealed that CRB2 enhances ovarian cancer cell proliferation, migration, and invasion, while suppressing apoptosis. Immunofluorescence staining of planar cell polarity markers demonstrated that CRB2 induces polarity alterations in EOC cells. Furthermore, Western blot analysis suggested that CRB2 may activate the Wnt/planar cell polarity (PCP) signalling pathway, contributing to tumour progression. These findings identify CRB2 as a key modulator of cell polarity and a potential driver of EOC aggressiveness. CRB2 may serve as a novel prognostic biomarker and therapeutic target for epithelial ovarian cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynaecology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital South Campu, Shanghai, China.
- Graduate Student Training Base of Jinzhou Medical University (Shanghai Fengxian District Central Hospital), Shanghai, China.
- Department of Obstetrics, Obstetrics & Gynaecology Hospital of Fudan University, Yangtze River Delta Integration Demonstration Zone(QingPu), Shanghai, China.
- Department of Gynecologic Oncology, Shanghai Geriatric Medical Center, Shanghai, China.
- Department of Gynaecology, Shanghai Xuhui Central Hospital, Zhongshan- Xuhui Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Chunlin Tao, Shaojing Li
Förderung
- National Natural Science Foundation of China
- Social Science and Technology Development Fund of Fengxian District Science and Technology Commission
Zitieren
APA
Tao, C., Li, S., Sun, D., Zhou, J., Chen, Y., Zhang, R., & Ni, X. (2026). CRB2 Facilitates Epithelial Ovarian Cancer Progression by Inducing Polarity Changes via Activation of the Wnt/ PCP Signalling Pathway. Journal of Cellular and Molecular Medicine, 30(7). https://doi.org/10.1111/jcmm.71124
Vancouver
Tao C, Li S, Sun D, Zhou J, Chen Y, Zhang R, et al. CRB2 Facilitates Epithelial Ovarian Cancer Progression by Inducing Polarity Changes via Activation of the Wnt/ PCP Signalling Pathway. Journal of Cellular and Molecular Medicine. 2026;30(7). doi:10.1111/jcmm.71124
BibTeX
@article{Tao2026,
author = {Tao, Chunlin and Li, Shaojing and Sun, Duohe and Zhou, Jun and Chen, Yuanping and Zhang, Rong and Ni, Xiaoge},
title = {CRB2 Facilitates Epithelial Ovarian Cancer Progression by Inducing Polarity Changes via Activation of the Wnt/ PCP Signalling Pathway},
journal = {Journal of Cellular and Molecular Medicine},
year = {2026},
volume = {30},
number = {7},
doi = {10.1111/jcmm.71124}
}
EUVIMED